{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:50:37Z","timestamp":1787611837428,"version":"build-2736575974"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiotoxicity, as a side effect of chemotherapeutic treatments, represents a major limiting factor during anti-tumour therapies. This is usually evident by decreased cardiac function, and the cardiovascular diseases linked to chemotherapeutic agents can range from mild arrhythmias and hypertension to myocardial injuries and heart failure. One of the most important regulators of cardiovascular function is nitric oxide (NO), a small signalling molecule associated with multiple cardioprotective properties. The activity of NO producing enzymes, the nitric oxide synthases (NOSs), is tightly regulated by pathways responsible for maintaining the cardiovascular NO homeostasis. Thus, the dysregulation of the NO\/NOS system could lead to severe pathologic changes in cardiomyocytes and endothelial cells. This narrative review examines the evidence on how chemotherapeutic agents affect cardiac NOS activity and NO signalling, and explores whether NO\/NOS dysregulation may be considered as a relevant mechanism in the development of chemotherapy-induced cardiotoxicity.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1682471","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:21:30Z","timestamp":1763101290000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["NO\/NOS system dysregulation as a key molecular mechanism in chemotherapy-induced cardiotoxicity: a review"],"prefix":"10.3389","volume":"12","author":[{"given":"Andr\u00e1s","family":"Nagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Vir\u00e1g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"B\u00f6rzsei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","article-title":"Cancer","year":""},{"key":"B2","article-title":"Cardiovascular diseases (CVDs) (2021)","year":""},{"key":"B3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/978-3-319-26387-8_33","article-title":"Chemotherapy-induced toxicities","volume-title":"Oncologic Emergency Medicine: Principles and Practice","author":"Toale","year":"2016"},{"key":"B4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2217\/fon.15.349","article-title":"Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity","volume":"12","author":"Wickramasinghe","year":"2016","journal-title":"Future Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/eurheartj\/ehaa013","article-title":"Cardiotoxicity\u2019: time to define new targets?","volume":"41","author":"Pardo Sanz","year":"2020","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/eci.12589","article-title":"Update on cardiotoxicity of anti-cancer treatments","volume":"46","author":"Rosa","year":"2016","journal-title":"Eur J Clin Investig"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-024-07574-0","article-title":"A comprehensive overview on chemotherapy-induced cardiotoxicity: insights into the underlying inflammatory and oxidative mechanisms","author":"Nagy","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3904\/kjim.2016.017","article-title":"Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity","volume":"31","author":"Chung","year":"2016","journal-title":"Korean J Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1111\/bph.14800","article-title":"Nitric oxide signalling in the brain and its control of bodily functions","volume":"177","author":"Chachlaki","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12291-011-0108-4","article-title":"Biochemistry of nitric oxide","volume":"26","author":"Habib","year":"2011","journal-title":"Indian J Clin Biochem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.bbamcr.2016.01.021","article-title":"New signal transduction paradigms in anthracycline-induced cardiotoxicity","volume":"1863","author":"Ghigo","year":"2016","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1096\/fj.03-0724rev","article-title":"The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage","volume":"18","author":"Fogli","year":"2004","journal-title":"FASEB J"},{"key":"B14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-031-24778-1_7","article-title":"Role of nitric oxide synthases in doxorubicin-induced cardiomyopathy","volume-title":"Nitric Oxide: From Research to Therapeutics","author":"Akolkar","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"795602","DOI":"10.1155\/2015\/795602","article-title":"Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress","volume":"2015","author":"Angsutararux","year":"2015","journal-title":"Oxid Med Cell Longevity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","article-title":"Antineoplastic drug-induced cardiotoxicity: a redox perspective","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Physiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"116526","DOI":"10.1016\/j.lfs.2019.06.001","article-title":"Role of oxidative stress in cardiotoxicity of antineoplastic drugs","volume":"232","author":"Zhang","year":"2019","journal-title":"Life Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10787-021-00894-9","article-title":"Cardiac inflammation and fibrosis following chemo\/radiation therapy: mechanisms and therapeutic agents","volume":"30","author":"Yang","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","article-title":"Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide","volume":"84","author":"Ignarro","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/327524a0","article-title":"Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor","volume":"327","author":"Palmer","year":"1987","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/0006-2952(91)90581-O","article-title":"Isoforms of nitric oxide synthase characterization and purification from different cell types","volume":"42","author":"F\u00f6rstermann","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0896-6273(92)90104-L","article-title":"Nitric oxide, a novel neuronal messenger","volume":"8","author":"Bredt","year":"1992","journal-title":"Neuron"},{"key":"B24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2741\/4711","article-title":"What does \u201cNO-synthase\u201d stand for?","volume":"24","author":"Santolini","year":"2019","journal-title":"Front Biosci Landmark"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.3390\/ijms22179546","article-title":"The role of the BH4 cofactor in nitric oxide synthase activity and cancer progression: two sides of the same coin","volume":"22","author":"Gon\u00e7alves","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.freeradbiomed.2017.08.025","article-title":"The NO-heme signaling hypothesis","volume":"112","author":"Kleschyov","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41589-023-01411-5","article-title":"NO-ferroheme is a signaling entity in the vasculature","volume":"19","author":"Kleschyov","year":"2023","journal-title":"Nat Chem Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/j.cell.2022.06.010","article-title":"Nitric oxide signaling in health and disease","volume":"185","author":"Lundberg","year":"2022","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1083\/jcb.200601051","article-title":"Identification of Golgi-localized acyl transferases that palmitoylate and regulate endothelial nitric oxide synthase","volume":"174","author":"Fern\u00e1ndez-Hernando","year":"2006","journal-title":"J Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.freeradbiomed.2010.04.004","article-title":"Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease","volume":"49","author":"Villanueva","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/FJC.0000000000000817","article-title":"Targets of cGMP\/cGKI in cardiac myocytes","volume":"75","author":"Adler","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1161\/CIRCRESAHA.109.207381","article-title":"S-nitrosylation in cardiovascular signaling","volume":"106","author":"Lima","year":"2010","journal-title":"Circ Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11906-012-0320-5","article-title":"Pathophysiology of hypertension in the absence of nitric oxide\/cyclic GMP signaling","volume":"15","author":"Thoonen","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1073\/pnas.1113319109","article-title":"Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function","volume":"109","author":"Beigi","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1038\/emm.2013.112","article-title":"PPAR\u03b3 modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury","volume":"45","author":"Yang","year":"2013","journal-title":"Exp Mol Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"C824","DOI":"10.1152\/ajpcell.00592.2005","article-title":"Nitric oxide-induced inhibition of smooth muscle cell proliferation involves S-nitrosation and inactivation of RhoA","volume":"292","author":"Zuckerbraun","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-3-319-66224-4_15","article-title":"cGMP signaling in platelets","volume-title":"Platelets, Haemostasis and Inflammation","author":"Wen","year":"2017"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1073\/pnas.0408310102","article-title":"Regulation of platelet granule exocytosis by S-nitrosylation","volume":"102","author":"Morrell","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41401-021-00674-9","article-title":"S-nitrosylation of c-jun N-terminal kinase mediates pressure overload-induced cardiac dysfunction and fibrosis","volume":"43","author":"Zhou","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1111\/bph.15626","article-title":"Inhibition of HSP90 S-nitrosylation alleviates cardiac fibrosis via TGF\u03b2\/SMAD3 signalling pathway","volume":"178","author":"Zhang","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2000810","DOI":"10.1002\/mnfr.202000810","article-title":"Chlorogenic acid alleviates hyperglycemia-induced cardiac fibrosis through activation of the NO\/cGMP\/PKG pathway in cardiac fibroblasts","volume":"65","author":"Qin","year":"2021","journal-title":"Mol Nutr Food Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14336\/AD.2022.0523","article-title":"The NO-cGMP-PKG axis in HFpEF: from pathological mechanisms to potential therapies","volume":"14","author":"Cai","year":"2023","journal-title":"Aging Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2008.10.029","article-title":"Preconditioning and postconditioning: underlying mechanisms and clinical application","volume":"204","author":"Hausenloy","year":"2009","journal-title":"Atherosclerosis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/1535370214522935","article-title":"Protein S-nitrosylation in preconditioning and postconditioning","volume":"239","author":"Penna","year":"2014","journal-title":"Exp Biol Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.niox.2017.02.003","article-title":"Interaction between nitric oxide signaling and gap junctions during ischemic preconditioning: importance of S-nitrosylation vs. protein kinase G activation","volume":"65","author":"Xie","year":"2017","journal-title":"Nitric Oxide"},{"key":"B46","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ejphar.2015.09.018","article-title":"Inhibition of the nitric oxide\/cyclic guanosine monophosphate pathway limited the cardioprotective effect of post-conditioning in hearts with apical myocardial infarction","volume":"765","author":"Correa","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.freeradbiomed.2012.09.005","article-title":"Essential role of nitric oxide in acute ischemic preconditioning: s-nitros (yl) ation versus sGC\/cGMP\/PKG signaling?","volume":"54","author":"Sun","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s11658-023-00423-2","article-title":"Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets","volume":"28","author":"Janaszak-Jasiecka","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"B49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/ijms20010187","article-title":"New therapeutic implications of endothelial nitric oxide synthase (eNOS) function\/dysfunction in cardiovascular disease","volume":"20","author":"Daiber","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1073\/pnas.0409594102","article-title":"Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase","volume":"102","author":"Chalupsky","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","first-page":"10012","DOI":"10.1038\/s41598-020-66639-w","article-title":"Non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease","volume":"10","author":"Dao","year":"2020","journal-title":"Sci Rep"},{"key":"B52","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1172\/JCI0213265","article-title":"Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death","volume":"109","author":"Mungrue","year":"2002","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"16304","DOI":"10.1074\/jbc.M212321200","article-title":"JAK2\/STAT3, Not ERK1\/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes","volume":"278","author":"Yu","year":"2003","journal-title":"J Biol Chem"},{"key":"B54","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00414-019-02051-y","article-title":"Increased inducible nitric oxide synthase (iNOS) expression in human myocardial infarction","volume":"134","author":"Wilmes","year":"2020","journal-title":"Int J Leg Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"7738","DOI":"10.3390\/jcm12247738","article-title":"Inflammation in heart failure\u2014future perspectives","volume":"12","author":"Arvunescu","year":"2023","journal-title":"J Clin Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jprot.2019.01.001","article-title":"The protein S-nitrosylation of splicing and translational machinery in vascular endothelial cells is susceptible to oxidative stress induced by oxidized low-density lipoprotein","volume":"195","author":"Xu","year":"2019","journal-title":"J Proteomics"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/antiox9111051","article-title":"Post-translational S-nitrosylation of proteins in regulating cardiac oxidative stress","volume":"9","author":"Shi","year":"2020","journal-title":"Antioxidants"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3892\/mmr.2014.2968","article-title":"Nitric oxide synthases, S-nitrosylation and cardiovascular health: from molecular mechanisms to therapeutic opportunities","volume":"11","author":"Treuer","year":"2015","journal-title":"Mol Med Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1073\/pnas.0300464101","article-title":"S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity","volume":"101","author":"Ravi","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1089\/ars.2012.4744","article-title":"S-nitrosothiols and the S-nitrosoproteome of the cardiovascular system","volume":"18","author":"Maron","year":"2013","journal-title":"Antioxid Redox Signaling"},{"key":"B61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1389200216666151103114926","article-title":"The role of the metabolism of anticancer drugs in their induced-cardiotoxicity","volume":"17","author":"Filipa Reis-Mendes","year":"2016","journal-title":"Curr Drug Metab"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1111\/jcmm.14130","article-title":"Ursolic acid prevents doxorubicin-induced cardiac toxicity in mice through eNOS activation and inhibition of eNOS uncoupling","volume":"23","author":"Mu","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"11293","DOI":"10.1021\/bi971475e","article-title":"Endothelial nitric oxide synthase-dependent superoxide generation from Adriamycin","volume":"36","author":"V\u00e1squez-Vivar","year":"1997","journal-title":"Biochemistry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1161\/CIRCULATIONAHA.106.684795","article-title":"Proteasome-dependent degradation of guanosine 5\u2032-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus","volume":"116","author":"Xu","year":"2007","journal-title":"Circulation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"9890","DOI":"10.3390\/ijms25189890","article-title":"Replicative endothelial cell senescence may lead to endothelial dysfunction by increasing the BH2\/BH4 ratio induced by oxidative stress, reducing BH4 availability, and decreasing the expression of eNOS","volume":"25","author":"Hernandez-Navarro","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4274\/Tjh.2012.0013","article-title":"The role of nitric oxide in doxorubicin-induced cardiotoxicity: experimental study","volume":"31","author":"Bahad\u0131r","year":"2014","journal-title":"Turk J Hematol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00210-009-0407-y","article-title":"Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice","volume":"380","author":"Deng","year":"2009","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000512771","article-title":"Anthracycline-induced cardiotoxicity: the role of endothelial dysfunction","volume":"146","author":"Grakova","year":"2021","journal-title":"Cardiology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/ars.2015.6542","article-title":"Decreased soluble guanylate cyclase contributes to cardiac dysfunction induced by chronic doxorubicin treatment in mice","volume":"26","author":"Vandenwijngaert","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"B70","doi-asserted-by":"publisher","first-page":"109190","DOI":"10.1016\/j.cbi.2020.109190","article-title":"BAY60-2770 Attenuates doxorubicin-induced cardiotoxicity by decreased oxidative stress and enhanced autophagy","volume":"328","author":"Zhao","year":"2020","journal-title":"Chem-Biol Interact"},{"key":"B71","author":"Chen","year":""},{"key":"B72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/FJC.0000000000000350","article-title":"Docosahexaenoic acid attenuates doxorubicin-induced cytotoxicity and inflammation by suppressing NF-\u03baB\/iNOS\/NO signaling pathway activation in H9C2 cardiac cells","volume":"67","author":"Wang","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.taap.2016.01.006","article-title":"Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity","volume":"293","author":"Pecoraro","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-019-2686-2","article-title":"Protective effect of shenmai injection on doxorubicin-induced cardiotoxicity via regulation of inflammatory mediators","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Complement Altern Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.yjmcc.2006.11.016","article-title":"Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress","volume":"42","author":"Andreadou","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/toxres\/tfac023","article-title":"Synergistic impacts of montelukast and klotho against doxorubicin-induced cardiac toxicity in rats","volume":"11","author":"Elnoury","year":"2022","journal-title":"Toxicol Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"6628957","DOI":"10.1155\/2021\/6628957","article-title":"Protection against doxorubicin-induced cardiotoxicity through modulating iNOS\/ARG 2 balance by electroacupuncture at PC6","volume":"2021","author":"Wang","year":"2021","journal-title":"Oxid Med Cell Longevity"},{"key":"B78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12012-021-09710-w","article-title":"Curcumin ameliorates doxorubicin-induced cardiotoxicity and hepatotoxicity via suppressing oxidative stress and modulating iNOS, NF-\u03baB, and TNF-\u03b1 in rats","volume":"22","author":"Ibrahim Fouad","year":"2022","journal-title":"Cardiovasc Toxicol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2014.01.065","article-title":"Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis","volume":"728","author":"Mantawy","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/antiox10121897","article-title":"Endoplasmic reticulum stress promotes iNOS\/NO and influences inflammation in the development of doxorubicin-induced cardiomyopathy","volume":"10","author":"Bagchi","year":"2021","journal-title":"Antioxidants"},{"key":"B81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.yjmcc.2004.10.012","article-title":"Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation","volume":"38","author":"Maejima","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","article-title":"Fluoropyrimidine-associated cardiotoxicity","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol Clin"},{"key":"B83","doi-asserted-by":"publisher","first-page":"14693","DOI":"10.1038\/s41598-020-71531-8","article-title":"Activated ROCK\/akt\/eNOS and ET-1\/ERK pathways in 5-fluorouracil-induced cardiotoxicity: modulation by simvastatin","volume":"10","author":"Muhammad","year":"2020","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","first-page":"153042","DOI":"10.1016\/j.tox.2021.153042","article-title":"Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity","volume":"465","author":"Refaie","year":"2022","journal-title":"Toxicology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12012-024-09958-y","article-title":"Cardiotoxicity associated with a low doses of 5-FU promotes morphoquantitative changes in the intrinsic cardiac nervous system","volume":"25","author":"da Costa Salom\u00e3o","year":"2025","journal-title":"Cardiovasc Toxicol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"R793","DOI":"10.1152\/ajpregu.00713.2007","article-title":"IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction","volume":"294","author":"Ren","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.freeradbiomed.2011.03.010","article-title":"Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency","volume":"50","author":"Crabtree","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3892\/mmr.2017.6225","article-title":"Methotrexate improves perivascular adipose tissue\/endothelial dysfunction via activation of AMPK\/eNOS pathway","volume":"15","author":"Ma","year":"2017","journal-title":"Mol Med Rep"},{"key":"B89","doi-asserted-by":"publisher","first-page":"102035","DOI":"10.1016\/j.tice.2023.102035","article-title":"Naringin ameliorates 5-fluorouracil induced cardiotoxicity: an insight into its modulatory impact on oxidative stress, inflammatory and apoptotic parameters","volume":"81","author":"Gui","year":"2023","journal-title":"Tissue and Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12012-025-09962-w","article-title":"Taxifolin protects against 5-fluorouracil-induced cardiotoxicity in mice through mitigating oxidative stress, inflammation, and apoptosis: possible involvement of Sirt1\/Nrf2\/HO-1 signaling","volume":"25","author":"Abukhalil","year":"2025","journal-title":"Cardiovasc Toxicol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"8641026","DOI":"10.1155\/2020\/8641026","article-title":"Paeonol attenuates methotrexate-induced cardiac toxicity in rats by inhibiting oxidative stress and suppressing TLR4-induced NF-\u03baB inflammatory pathway","volume":"2020","author":"Al-Taher","year":"2020","journal-title":"Mediat Inflamm"},{"key":"B92","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.26355\/eurrev_202110_26879","article-title":"Assessment of the cardioprotective effect of liraglutide on methotrexate induced cardiac dysfunction through suppression of inflammation and enhancement of angiogenesis in rats","volume":"25","author":"Mahmoud","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00204-020-02971-4","article-title":"Human family 1\u20134 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update","volume":"95","author":"Rendic","year":"2021","journal-title":"Arch Toxicol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.yjmcc.2008.03.020","article-title":"Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKC\u03b5 signaling and cardioprotection","volume":"44","author":"Wang","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"H2050","DOI":"10.1152\/ajpheart.00120.2011","article-title":"Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy","volume":"301","author":"Ismahil","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-016-3233-1","article-title":"Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate","volume":"79","author":"El-Agamy","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"172666","DOI":"10.1016\/j.ejphar.2019.172666","article-title":"Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss albino mice","volume":"863","author":"Iqubal","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"102007","DOI":"10.1016\/j.toxrep.2025.102007","article-title":"Chrysin mitigates cyclophosphamide-triggered cardiotoxicity in rats: insights into cardioprotection via treg expression modulation and iNOS downregulation","volume":"14","author":"Saleh","year":"2025","journal-title":"Toxicol Rep"},{"key":"B99","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.tcb.2018.05.001","article-title":"Microtubule-targeting agents: strategies to hijack the cytoskeleton","volume":"28","author":"Steinmetz","year":"2018","journal-title":"Trends Cell Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.intimp.2003.08.007","article-title":"The immunopharmacology of paclitaxel (taxol\u00ae), docetaxel (taxotere\u00ae), and related agents","volume":"3","author":"Fitzpatrick","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/cvr\/cvab055","article-title":"Paclitaxel mitigates structural alterations and cardiac conduction system defects in a mouse model of hutchinson\u2013gilford progeria syndrome","volume":"118","author":"Mac\u00edas","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B102","first-page":"221","article-title":"Cardioprotective effect of royal jelly on paclitaxel-induced cardio-toxicity in rats","volume":"19","author":"Malekinejad","year":"2016","journal-title":"Iran J Basic Med Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"8192","DOI":"10.1158\/0008-5472.CAN-06-0748","article-title":"Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation","volume":"66","author":"Murtagh","year":"2006","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1158\/0008-5472.CAN-04-4095","article-title":"Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1\u03b1 accumulation and activity by disrupting microtubule function","volume":"65","author":"Escuin","year":"2005","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"77","DOI":"10.51040\/dkmj.2023-033","article-title":"Decreased SIRT1 impairs HIF-1\u03b1 nuclear translocation in alveolar epithelial cells: a potential mechanism of emphysema progression","volume":"3","author":"To","year":"2024","journal-title":"Dokkyo Med J"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3389\/fonc.2019.01516","article-title":"Role of sirtuins in tumor angiogenesis","volume":"9","author":"Edatt","year":"2020","journal-title":"Front Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2009.01.072","article-title":"Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation","volume":"53","author":"Ota","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.critrevonc.2016.06.009","article-title":"Therapeutic potential and critical analysis of trastuzumab and bevacizumab in combination with different chemotherapeutic agents against metastatic breast\/colorectal cancer affecting various endpoints","volume":"104","author":"Wahid","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrcardio.2013.94","article-title":"Vascular endothelial growth factor in heart failure","volume":"10","author":"Taimeh","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e0178619","DOI":"10.1371\/journal.pone.0178619","article-title":"Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"B113","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B115","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.redox.2015.09.007","article-title":"Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors","volume":"6","author":"Le\u00f3n-Mateos","year":"2015","journal-title":"Redox Biol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000476016","article-title":"Vascular endothelial growth factor augments arginine transport and nitric oxide generation via a KDR receptor signaling pathway","volume":"42","author":"Shashar","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor\u2013signaling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"key":"B121","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/CMAR.S77400","article-title":"Cancer therapy and cardiovascular risk: focus on bevacizumab","volume":"7","author":"Economopoulou","year":"2015","journal-title":"Cancer Manag Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1358850","DOI":"10.3389\/fphys.2024.1358850","article-title":"The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer","volume":"15","author":"O\u2019Neill","year":"2024","journal-title":"Front Physiol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"B125","first-page":"1147","article-title":"Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer","volume":"34","author":"Sandoo","year":"2014","journal-title":"Anticancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cjca.2013.11.013","article-title":"Congenital absence of nitric oxide synthase 3 potentiates cardiac dysfunction and reduces survival in doxorubicin-and trastuzumab-mediated cardiomyopathy","volume":"30","author":"Zeglinski","year":"2014","journal-title":"Can J Cardiol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.7150\/thno.23207","article-title":"The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling","volume":"8","author":"Hsu","year":"2018","journal-title":"Theranostics"},{"key":"B128","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2017.05.019","article-title":"Arginine-Nitric oxide metabolites and cardiac dysfunction in patients with breast cancer","volume":"70","author":"Finkelman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"5681510","DOI":"10.1155\/2022\/5681510","article-title":"Sildenafil for primary prevention of anthracycline-induced cardiac toxicity: a phase I\/II randomized clinical trial, SILDAT-TAHA6 trial","volume":"2022","author":"Attar","year":"2022","journal-title":"Cardiol Res Pract"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2202353","DOI":"10.1183\/13993003.02353-2022","article-title":"Oral nitrate supplementation improves cardiovascular risk markers in COPD: ON-BC, a randomised controlled trial","volume":"63","author":"Alasmari","year":"2024","journal-title":"Eur Respir J"},{"key":"B131","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.jhh.1002329","article-title":"Tetrahydrobiopterin: a novel antihypertensive therapy","volume":"22","author":"Porkert","year":"2008","journal-title":"J Hum Hypertens"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1042\/CS20200301","article-title":"Molecular mechanisms of anthracycline cardiovascular toxicity","volume":"135","author":"Narezkina","year":"2021","journal-title":"Clin Sci"},{"key":"B133","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11936-020-00842-w","article-title":"Doxorubicin cardiotoxicity: pathophysiology updates","volume":"22","author":"Hoeger","year":"2020","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-015-3437-9","article-title":"Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients","volume":"152","author":"Vulsteke","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B136","doi-asserted-by":"publisher","first-page":"S553","DOI":"10.1177\/09603271211033774","article-title":"Idarubicin-induced oxidative stress and apoptosis in cardiomyocytes: an in vitro molecular approach","volume":"40","author":"Zhang","year":"2021","journal-title":"Hum Exp Toxicol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jgr.2022.06.002","article-title":"Ginsenoside F1 attenuates pirarubicin-induced cardiotoxicity by modulating Nrf2 and AKT\/bcl-2 signaling pathways","volume":"47","author":"Zhang","year":"2023","journal-title":"J Ginseng Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/ph16091312","article-title":"The impact of metformin on the development of hypothyroidism and cardiotoxicity induced by cyclophosphamide, methotrexate, and fluorouracil in rats","volume":"16","author":"Alhowail","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B139","doi-asserted-by":"publisher","first-page":"733","DOI":"10.22038\/IJBMS.2024.74161.16120","article-title":"Effect of vitamin B12 on methotrexate-induced cardiotoxicity in rats","volume":"27","author":"Kulo\u011flu","year":"2024","journal-title":"Iran J Basic Med Sci"},{"key":"B140","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J Clin Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.08.001","article-title":"The role of pharmacogenetics in capecitabine efficacy and toxicity","volume":"50","author":"Lam","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7603\/s40730-015-0005-1","article-title":"Molecular basis of drug interactions of methotrexate, cyclophosphamide and 5-fluorouracil as chemotherapeutic agents in cancer","volume":"2","author":"Sarder","year":"2015","journal-title":"Biomed Res Therapy"},{"key":"B144","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/978-981-33-6009-9_63","article-title":"Cytotoxic drugs","volume-title":"Introduction to Basics of Pharmacology and Toxicology: Volume 2: Essentials of Systemic Pharmacology: From Principles to Practice","author":"Benjamin","year":"2021"},{"key":"B145","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/10520295.2023.2253424","article-title":"Selenium protection from DNA damage and regulation of apoptosis signaling following cyclophosphamide induced cardiotoxicity in rats","volume":"98","author":"\u0130pek","year":"2023","journal-title":"Biotech Histochem"},{"key":"B146","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaccao.2019.09.007","article-title":"Cancer therapy-related cardiac dysfunction of nonanthracycline chemotherapeutics: what is the evidence?","volume":"1","author":"Kamphuis","year":"2019","journal-title":"Cardio Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies","volume":"650","author":"El-Awady","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-021-01014-0","article-title":"Microtubule inhibitors and cardiotoxicity","volume":"23","author":"Joshi","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1097\/MJT.0000000000000453","article-title":"Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer","volume":"24","author":"Mihalcea","year":"2017","journal-title":"Am J Ther"},{"key":"B150","doi-asserted-by":"publisher","first-page":"692970","DOI":"10.3389\/fphar.2021.692970","article-title":"Cardiovascular toxicity induced by chronic vincristine treatment","volume":"12","author":"Herrad\u00f3n","year":"2021","journal-title":"Front Pharmacol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"125","DOI":"10.17305\/bb.2023.9272","article-title":"MicroRNAs expression profile in chemotherapy-induced cardiotoxicity in non-small cell lung cancer using a co-culture model","volume":"24","author":"Romitan","year":"2024","journal-title":"Biomol Biomed"},{"key":"B152","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s13273-018-0027-z","article-title":"Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy","volume":"14","author":"Lee","year":"2018","journal-title":"Mol Cell Toxicol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast cancer treatment-induced cardiotoxicity","volume":"16","author":"Martel","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B155","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10549-017-4460-9","article-title":"Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis","volume":"166","author":"Choi","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B156","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/1440-1681.13181","article-title":"Breast cancer drugs perturb fundamental vascular functions of endothelial cells by attenuating protein S-nitrosylation","volume":"47","author":"Giri","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1682471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:21:33Z","timestamp":1763101293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1682471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":156,"alternative-id":["10.3389\/fcvm.2025.1682471"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1682471","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1682471"}}